Psyence Group

Psyence invites you to experience a deeper look into Psychedelic Health Investment Opportunities.

Date: April 13th 2023

RSVP essential

Register here - https://psyenceinvestment.rsvpify.com

Jody Aufrichtig, Co-founder, Executive Chairman Psyence Group - speaking at the 6th International Investment Forum.

"I believe we need to radically change the way we think about the future and the way we think about mental health. We need to make a difference. I believe we can and will deliver shareholder value and returns and that we can do this by making a big and positive impact on humanity."

Watch the presentation online:

6. IIF - Psyence Group Inc. Executive Chairman Jody Aufrichtig The ‘International Investment Forum’ – (‘IIF’) provides information on investment trends and ideas, covering all aspects of various industries, from top exec...

We are thrilled to have been featured on the iconic Nasdaq tower in Times Square, one of the most recognisable landmarks in the financial world - thank you Nasdaq.

Psyence Group's journey so far, as we seek to create a paradigm shift in the treatment of patients with an incurable illness, has achieved a number of exciting milestones.

This proposed transaction with Newcourt (Nasdaq: NCAC) is significant in that it will enable us to execute our early-stage development program in .

Congratulations to all our team involved in making this happen.

Our partnership with Eden Labs, a product development and extraction technology company that has developed intellectual property and methodologies around the extraction of -yielding mushrooms, will significantly expand our ability to bring valuable medical resources to the application of research worldwide.

We are excited to welcome Eden Lab's CEO AC Braddock to Psyence Group's Scientific Advisory Board. AC's experience in methodology and product development we believe will be invaluable.

Psyence and Eden Labs Announce Extraction and Product Development Collaboration Psyence and Eden Labs Announce Extraction and Product Development Collaboration TORONTO, ON/ 24 January 2023 / Psyence Group Inc. (CSE: PSYG. |. OTCQB: PSYGF) (Psyence or the Company), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is...

We are delighted to announce today that Psyence Group has attracted an investment from a member of the Kerzner family, undoubtedly one of South Africa’s most globally recognised family offices.

Net proceeds from this non-brokered private placement will be used to advance our palliative care clinical trial and our drug development programme.

It will also be used for enhancements at our ISO22000 production facility, and for general working capital.

Read more:

Psyence Group Announces Strategic Private Placement Psyence Group Announces Strategic Private Placement TORONTO, ON/ 10 NOVEMBER 2022 / Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to annou...